Led · Seed · May 2026

Autoimmunity BioSolutions is developing a personalized, genetically guided immuno-corrective therapy designed to normalize elevated levels of soluble IL7R (sIL7R), a driver of poor therapeutic response in autoimmune disease. The therapy targets a genetically defined subpopulation marked by a highly prevalent SNP estimated in roughly 50% of the population that increases sIL7R expression. ABS is focused on indications including rheumatoid arthritis, lupus nephritis, and type 1 diabetes where elevated sIL7R has been associated with greater severity, progression, and reduced response to standard treatments. The company plans near-term work to complete animal model studies and patient bio-sample analyses in rheumatoid arthritis. ABS has raised $3.1 million in total seed capital following the $1M seed extension and is headquartered in Houston. The company positions its approach as differentiated from immunosuppressive standards of care and aims to enhance response in refractory patient populations with elevated sIL7R.

Participated · Seed · Jan 2026

TECregen pioneers thymus regeneration with a pipeline of differentiated thymopoietic biologics designed to revitalize and expand thymic epithelial cells (TECs) and replenish T-cell populations. Its therapeutic approach targets conditions driven by impaired T-cell responses, aiming to boost immune recovery after transplantation or cytotoxic therapy, promote lifelong immune health, and improve immune surveillance against cancer. The platform also holds promise across broader immunology, oncology, and rare-disease indications. Fresh capital from a CHF 10 million seed financing provides the resources to advance preclinical programs toward first-in-human studies. The company has reinforced its leadership by appointing seasoned biotech executive Dr. Bo Rode Hansen as chairman to guide strategic growth. Backed by a syndicate of specialized life-science investors, TECregen is positioning itself at the forefront of immune-restoration therapeutics. No revenue or user metrics have been disclosed, as the company remains in the preclinical stage.

Participated · Series A · Oct 2024

Axonis is developing first-in-class oral small molecules that potentiate KCC2, a CNS chloride transporter crucial for inhibitory neurotransmission. Its lead candidate, AXN-027, is designed to restore functional inhibition and is being advanced into clinical proof-of-concept in patients with epilepsy and pain. The company plans to use its proprietary KCC2 discovery engine to develop next-generation compounds for additional indications including psychiatric and neurodevelopmental disorders. Axonis was spun out from Boston Children’s Hospital, Harvard and Université Laval and is headquartered in Boston, MA. Leadership includes co-founder and CEO Joanna Stanicka, Ph.D., CSO Shane Hegarty, Ph.D., and new appointments for Chief Medical Officer Donald Manning, M.D., Ph.D., and COO Jeff Imbaro. The company has received grant support from multiple public and non-profit sources and will use the recent financing to fund clinical development and pipeline expansion. AXONIS Therapeutics is an emerging biotechnology company based in Cambridge, MA, advancing neuromodulating therapies for central nervous system disorders. Its pipeline focuses on neuron-reviving approaches that enable CNS neurons to resist degeneration, restore excitation/inhibition balance, and regenerate. The company’s primary program centers on upmodulation of the KCC2 protein and has completed proof-of-concept preclinical studies showing reactivation of spared neural tissue at sites of spinal cord injury. Targeted indications include spinal cord injury and epilepsy, with potential applicability to chronic pain, Rett syndrome and broader neurodegenerative conditions. AXONIS has licensed three technologies, including recently discovered methods to prevent neurodegeneration, and is investigating additional methodologies to revive neurons. Financially, the company secured $4 million in seed funding at its operational launch in early 2020, has received non-dilutive awards from the Massachusetts Life Sciences Center and NIH SBIR and two Golden Tickets from Boehringer Ingelheim and Astellas, and just raised additional financing to support clinical advancement and IND-enabling activities. AXONIS Therapeutics is advancing a novel KCC2 upmodulation therapy to reactivate spared neural tissue after spinal cord injury and is also investigating PTEN inhibition to regenerate injured nerve connections. The company has licensed or optioned two technologies from Boston Children’s Hospital to support its preclinical programs. Proceeds from the current financing will enable AXONIS to conduct preclinical studies and expand its team as it moves toward proof-of-concept milestones. AXONIS reports promising proof-of-concept results to date and expects to deliver additional proof-of-concept data in approximately one year. The company has received state and federal non-dilutive funding and other seed investment, and won a Boehringer Ingelheim Golden Ticket that provides one year of free lab space at LabCentral. Leadership includes CEO Joanna Stanicka, PhD, Executive Chair and co-founder Corey Goodman, PhD, and founder Bob Yant; the company is based in Cambridge, MA.

Participated · Seed · Sep 2024

HDAX Therapeutics is developing best-in-class HDAC6-targeting small-molecule therapeutics via a novel molecular recognition mechanism aimed at overcoming weak binding, poor pharmacokinetics, and off-target toxicities. The company’s platform originates from over seven years of research in Professor Patrick Gunning’s lab at the University of Toronto. HDAX is focused on discovery and preclinical development toward candidate nomination across neurological and cardiometabolic indications. Management emphasizes the potential for differentiated safety and efficacy versus prior HDAC6 efforts. The company is privately held and plans to use proceeds from its seed financing to advance its pipeline programs and nominate a preclinical development candidate. HDAX highlights a leadership team with deep small-molecule development expertise.